


## Supporting information


# Supramolecular Prodrug Micelles Based on the Complementary Multiple Hydrogen Bonds as Drug Delivery Platform for Thrombosis Therapy

Wen'en Li,<sup>a,b</sup> Haibo Wang,<sup>c</sup> Zeliang Wei,<sup>b</sup> Juewei Ning,<sup>b</sup> Limei Ma,<sup>a,b</sup> Huajie Zheng,<sup>b</sup> Hai Niu<sup>\*b,d</sup> and Wen Huang<sup>\*a</sup>,


<sup>b</sup>



**Fig. S1.** <sup>13</sup>C NMR and <sup>1</sup>H NMR spectrum of compound 2 in CDCl<sub>3</sub>. (A) <sup>13</sup>C NMR (B) <sup>1</sup>H NMR



**Fig. S2.**  $^{13}\text{C}$  NMR and  $^1\text{H}$  NMR spectrum of compound 3 in  $\text{CDCl}_3$ . (A)  $^{13}\text{C}$  NMR (B)  $^1\text{H}$  NMR



**Fig. S3.** Mass spectrum of compound 3.




Fig. S4. <sup>13</sup>C NMR of D-T in CDCl<sub>3</sub>.




Fig. S5. The LC profile of D-T.







Fig. S6. Mass spectrum of D-T.



**Fig. S7.** Mass spectrum of PEG-U.



**Fig. S8.** <sup>13</sup>C NMR of uracil-terminated poly(ethylene glycol) (PEG-U) in CDCl<sub>3</sub>.



**Fig. S9.** Incubation with the prodrug micelles and diosgenin for 24 h inhibited the proliferation of and resulted in a morphological change in HK-2 and LO2 cells. (A) Incubation with the prodrug micelles and diosgenin for 24 h inhibited the proliferation of and resulted in a morphological change in HK-2 cells: (a)/(b) Control; (b)/(c) cells treated with 10 uM and 50 uM prodrug micelles; (e)/(f) cells treated with 10 uM and 50 uM diosgenin (B) Incubation with the prodrug micelles and diosgenin for 24 h inhibited the proliferation of and resulted in a morphological change in LO2 cells: (a)/(b) Control; (b)/(c) cells treated with 10 uM and 50 uM prodrug micelles; (e)/(f) cells treated with 10 uM and 50 uM diosgenin.